Babson Diagnostics, a US-based medical technology company, has raised $13.7m in its series A round led by Siemens Healthineers, the healthcare-fcoused division of Germany-based conglomerate Siemens.
Other investors in the round included venture capital firms Prism Ventures, Genesis Merchant Capital and Lago Consulting Group.
Originally incubated at Siemens Healthineers and developed in partnership with Becton Dickinson, Babson’s technology is designed to analyze capillary blood samples using only one-tenth the volume typically collected. Babson’s first-generation SARS-CoV-2 IgG antibody test received regulatory emergency use authorisation in June.
Deepak Nath, president of laboratory diagnostics for Siemens Healthineers, said: “The company continues to make great progress in democratising diagnostic blood testing and in contributing to the US’s fight against the covid-19 pandemic.”
